Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$21.70 USD
-1.08 (-4.74%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $21.70 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth C Momentum C VGM
Integra LifeSciences (IART) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$28.20 | $40.00 | $22.00 | 23.79% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Integra LifeSciences comes to $28.20. The forecasts range from a low of $22.00 to a high of $40.00. The average price target represents an increase of 23.79% from the last closing price of $22.78.
Analyst Price Targets (10)
Broker Rating
Integra LifeSciences currently has an average brokerage recommendation (ABR) of 3.22 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 2.89 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 16.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 16.67%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 6 | 6 | 6 |
Sell | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 3 | 3 | 1 | 1 | 1 |
ABR | 3.22 | 3.22 | 2.89 | 2.89 | 2.89 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/30/2024 | BTIG | Ryan Zimmerman | Hold | Strong Sell |
7/30/2024 | Not Identified | Not Identified | Hold | Strong Sell |
7/30/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
7/15/2024 | Not Identified | Not Identified | Hold | Hold |
5/7/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/7/2024 | Wells Fargo Securities | Vikramjeet S Chopra | Strong Buy | Hold |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Hold |
4/25/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.22 |
ABR (Last week) | 3.22 |
# of Recs in ABR | 12 |
Average Target Price | $28.20 |
LT Growth Rate | 12.00% |
Industry | Medical - Instruments |
Industry Rank by ABR | 147 of 253 |
Current Quarter EPS Est: | 0.45 |